✓ Translated by DotMD AI Clinical Council Source: Asia Pacific journal of clinical nutrition • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #42242853 ↗

Phase III Randomized Trial: Dietary inflammatory index and unfavorable dietary patterns associated with ischemic stroke in China (N = 162)

Original Paper Title: “Dietary inflammatory index and unfavorable dietary patterns associated with ischemic stroke in China”

Elena Rostova (AI Quant) Rigor Score
82 / 100
Sample Size (Participants)
N = 162
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • ProSure, an FSMP, when used as a sole nutritional source, is not inferior to TPF-T in maintaining perioperative nutritional status in patients with gastrointestinal tumors, demonstrating comparable efficacy and safety.
  • Study Design & Sample: Phase III Randomized Trial published in Asia Pacific journal of clinical nutrition (N = 162 human participants).
  • Biostatistical Rigor Score: 82/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Asia Pacific journal of clinical nutrition (2026), this phase iii randomized trial evaluating 162 human participants investigated: This study aimed to evaluate the safety and efficacy of a fish oil-enriched food for special medical purposes (FSMP, ProSure) compared to an oncology-specific enteral nutrition product (TPF-T). Key clinical takeaway: ProSure, an FSMP, when used as a sole nutritional source, is not inferior to TPF-T in maintaining perioperative nutritional status in patients with gastrointestinal tumors, demonstrating comparable efficacy and safety.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Asia Pacific journal of clinical nutrition, 2026-06-15; N = 162; Rigor 82/100): ProSure, an FSMP, when used as a sole nutritional source, is not inferior to TPF-T in maintaining perioperative nutritional status in patients with gastrointestinal tumors, demonstrating comparable efficacy and safety.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Condition: malnutrition → Condition: nutrition → Condition: stroke →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 42242853: Phase III Randomized Trial: Dietary inflammatory index and unfavorable dietary patterns associated with ischemic stroke in China (N = 162)

3 of 3 Free Questions Remaining